Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 836 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 45% confidence The document is a press release announcing clinical Phase 3 trial results and an upcoming virtual event. It does not contain financial statements or earnings guidance, nor is it a formal annual, interim, or audit report. It is not announcing board changes, dividends, share issues, or mergers, nor is it a call transcript. There is no investor slide deck attached, but rather a general corporate press release. As it does not fit a more specific filing category, it falls under the generic “Regulatory Filings” fallback category (RNS).
2026-06-08 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 85% confidence The document is a press release (“COMMUNIQUE DE PRESSE”) announcing the presentation of Phase 3 clinical trial data at an American Diabetes Association meeting, with no financial statements, management changes, or regulatory form references. It does not fit any specific financial or governance category and serves as a general announcement. Therefore, it is classified under Regulatory Filings (RNS) as a fallback.
2026-06-08 French
Inside Information / Other news releases
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing a virtual Key Opinion Leader (KOL) event to review Phase 3 clinical trial results. It does not present financial statements, earnings metrics, proxy materials, share actions, or fill any specific regulatory form category, nor is it an investor presentation deck itself. It is a general announcement and thus falls into the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2026-06-04 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 45% confidence The document is a corporate press release announcing a virtual event to present Phase 3 clinical trial results. It does not provide financial data or constitute an earnings release, investor presentation slides, a dividend or capital change notice, nor a formal report filing. It is therefore a general regulatory news announcement that does not fit the more specific categories and should be classified as a Regulatory Filing (RNS).
2026-06-04 French
Inside Information / News release on accounts, results
Earnings Release Classification · 90% confidence The document is titled as a press release reporting first quarter 2026 financial results and a business update. It contains summarized revenue figures, cash position, net debt, financing events, post-period updates, and highlights (e.g., board composition changes, product pipeline developments). It does not present full audited financial statements or a comprehensive interim report format, but rather a concise announcement of quarterly results and key business developments. This aligns with an Earnings Release (initial announcement of quarterly/periodical financial results). Q1 2026
2026-05-12 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 90% confidence The document is a press release titled “Adocia publie ses résultats financiers du premier trimestre 2026,” it provides headline Q1 financial results (revenues, cash position, debt) in tabular form, commentary from management, and operational updates. It is not a full interim report (with complete financial statements and notes) but rather an initial earnings announcement for the quarter. Thus it fits the Earnings Release category. Q1 2026
2026-05-12 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.